Portal vein thrombosis in a patient with HIV treated with a protease inhibitor-containing regimen

Acta Clinica Belgica

Volumn 61, Issue 1, 2006, Pages 24-29

  Soentjens, P ^a   Ostyn, B ^b   Van Outryve, S ^b   Ysebaert, D ^b   Vekemans, M ^b   Colebunders, R ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Factor VIII; Highly active antiretroviral therapy; Human immunodeficiency virus; Hyperhomocysteinemia; Portal vein thrombosis; Protein S deficiency; Splenorenal shunt; Von Willebrand antigen

Indexed keywords

ABACAVIR; AMPRENAVIR; BLOOD CLOTTING FACTOR 8; CABERGOLINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; ESOPHAGUS VARICES BLEEDING; FEMALE; HEMATEMESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERHOMOCYSTEINEMIA; PORTAL VEIN THROMBOSIS; PROTEIN S DEFICIENCY; RISK FACTOR; SPLENORENAL SHUNT; THROMBOEMBOLISM;

EID: 33645577395     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2006.005     Document Type: Article

References (39)

1. Saber AA, Aboolian A, La Raja RD, Baron H, Hanna K. HIV/AIDS and the risk of DVT: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67(7): 645-7.
2. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Project. AIDS 2000; 14: 321-4.
3. Wilkes MS, Fortwin AH, Felix JC, Godwin TA, Thompson WG. Value of necropsy in acquired immunodeficiency syndrome. Lancet 1988; 2: 85-8.
4. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15(1): 15-24.
5. Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, Montiel-Manzano C, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost 2004; 10(1): 19-25.
6. Lamaury I, Brouzes F, Sow MT, Pelczar S, Roul S, Strobel M. Portal thrombosis, mesenteric infarction and anticardiolipin antibodies in a patient with AIDS. Ann Med Interne (Paris) 1996; 147(5): 344-5.
7. Bouchard O, Bosseray A, Leclercq P, Micoud M. Portal thrombosis and anticardiolipin antibodies association in an HIV-2 infected patient. Presse Med 1998; 27(20): 965.
8. Carr A, Brown D, Cooper DA. Portal vein thrombosis in patients receiving indinavir, a HIV protease inhibitor. AIDS 1997; 11(13): 1657-8.
9. Locutura J, Lorenzo JF, Mijan A. Portal thrombosis in a female patient treated with protease inhibitors. Med Clin (Barc) 1999; 112(9): 359.
10. Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39(8): 1214-22.
11. Ramanampamonjy RM, Ramarozatovo LS, Bonnet F, Lacoste D, Rambeloarisoa J. Portal vein thrombosis in HIV-infected patients: report of four cases. Rev Med Interne 2005; 26(7): 545-8.
12. Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med 1992; 92: 173-82.
13. Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002; 16(5): 205-9.
14. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15(6): 311-20.
15. Simon DI, Xu H, Vaughan DE. Cathepsine D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. Biochim Biophys Acta 1995; 1268(2): 143-51.
16. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995: 95(3): 995-1001.
17. de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14(1): 15-8.
18. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185(4): 456-62.
19. Toulon P. Hemostasis and human immunodeficiency virus (HIV) infection. Ann Biol Clin (Paris) 1998; 56(2): 153-60.
20. Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-80.
21. Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256(4): 491-3.
22. Gris JC, Toulon P, Brun S, et al. The relationship between plasma microparticles, protein S, and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb Haemost 1996; 76(1): 38-45.
23. Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr. 1992; 5(5): 484-9.
24. Lafeuillade A, Alessi MC, Poizot-Martin IV, et al. Protein S deficiency and HIV infection. N Engl J Med 1991; 324: 1220.
25. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Eng J Med 1996; 334(12): 759-62.
26. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thrombo-embolic disease. Arch Intern Med 1998; 158(19): 2101-6.
27. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A. Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001; 15(8): 1081-2.
28. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on casuality from a meta-analysis. BMJ 2002; 325(7374): 1202.
29. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. lancet 1995; 345: 152-5.
30. Kraaijenhagen RA, in 't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83(1): 5-9.
31. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343(7): 457-62.
32. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81(7): 1801-7.
33. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9(4): 325-31.
34. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies. Thromb Res 1994; 73(3-4): 165-75.
35. George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999; 107(6): 624-6.
36. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 441-9.
37. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003; 110(2-3): 93-8.
38. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
39. Callens S, Florence E, Philippe M, Van der Planken M, Colebunders R. Mixed arterial and venous thromboembolism in a person with HIV infection. Scan J Infect Dis 2003; 35: 907-8.